Vivo Bio Tech Reports Strong Q1 FY2026 Performance with 29.66% Revenue Growth Aug 14, 2025
More news about Vivo Bio Tech
04Aug 25
Vivo Bio Tech Shareholders Approve Increase in Authorized Share Capital
Vivo Bio Tech Limited secured shareholder approval to increase its authorized share capital and alter the Capital Clause of its Memorandum of Association. The resolution passed with 99.81% votes in favor, with a 31.47% overall participation rate. The Promoter and Promoter Group showed 100% support with a 68.78% participation rate. This approval could enable the company to raise additional funds, potentially for growth strategies or expansion plans.